Xerimis is expanding its Business Development group due to increasing opportunities worldwide. This uptick of interest in Xerimis is due in part to the opening of its purpose-built, 13,000-square-foot United Kingdom facility in 2016. This is the second location for the privately held, New Jersey-headquartered clinical packaging provider. Located thirty minutes west of Heathrow and within easy access of London, the MHRA-approved space is designed to receive, store, label, package and distribute clinical supplies worldwide. The facility holds WDA, MIA-IMP, MS and MIA licenses. Three QPs named on the MIA-IMP license provide services ranging from QP Declaration for CTA submission to QP certification of finished, packaged supplies.
This photo shows the new team. From left to right:
Tom Brady joins Xerimis as Director of BD, North America. In the previous 6 years, Tom has successfully guided global and regional studies to completion with numerous sponsor clients. He brings a microbiology degree and 20 years of business development experience to the team. As his title suggests, Tom will be working with sponsor companies throughout North America to satisfy their clinical supply needs. (email@example.com)
Puvi Bala shifts her focus from leading the construction and opening of Xerimis’ UK facility to bringing clients to that facility. A practicing pharmacist, Puvi will be working with sponsor companies in Europe and beyond. She will continue to be one of the Responsible Persons in the WDA license. Her extensive understanding of Xerimis’ UK site will suit her well in her new role as Director of BD, Europe. (firstname.lastname@example.org)
Kevin Clover accepts his new role of Sr. Director, Global BD after 7 years as the Business Development Executive at Xerimis. In this expanded role, Kevin will provide oversight of Xerimis’ marketing and sales initiatives as well as a particular focus on sponsor clients outside the US and EU. (email@example.com)
“We are proud to have assembled this talented and experienced team to support our growth,” said Jim LoCascio, VP Strategic and Business Development. “Xerimis is well positioned to support the packaging and distribution of global clinical studies and our BD team is excited about educating prospective clients on our extensive capabilities.”